534 related articles for article (PubMed ID: 27080976)
41. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
42. Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric Stages 3 and 4 chronic kidney disease (CKD).
Smith ER; Lee D; Cai MM; Tomlinson LA; Ford ML; McMahon LP; Holt SG
Nephrol Dial Transplant; 2013 Jun; 28(6):1569-79. PubMed ID: 23328709
[TBL] [Abstract][Full Text] [Related]
43. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
44. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT
Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012
[TBL] [Abstract][Full Text] [Related]
45. Proton pump inhibitor use is not associated with cardiac arrhythmia in critically ill patients.
Chen KP; Lee J; Mark RG; Feng M; Celi LA; Malley BE; Danziger J
J Clin Pharmacol; 2015 Jul; 55(7):774-9. PubMed ID: 25655574
[TBL] [Abstract][Full Text] [Related]
46. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: Two nationwide studies.
Cherng YG; Lin CS; Shih CC; Hsu YH; Yeh CC; Hu CJ; Chen TL; Liao CC
PLoS One; 2018; 13(1):e0191155. PubMed ID: 29329323
[TBL] [Abstract][Full Text] [Related]
47. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
[TBL] [Abstract][Full Text] [Related]
48. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
49. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
Hughes J; Y Y Chiu D; Kalra PA; Green D
PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
[TBL] [Abstract][Full Text] [Related]
50. Use of Proton Pump Inhibitors Increases Risk of Incident Kidney Stones.
Simonov M; Abel EA; Skanderson M; Masoud A; Hauser RG; Brandt CA; Wilson FP; Laine L
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):72-79.e21. PubMed ID: 32147588
[TBL] [Abstract][Full Text] [Related]
51. Contrast Medium Exposure During Computed Tomography and Risk of Development of End-Stage Renal Disease in Patients With Chronic Kidney Disease: A Nationwide Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study.
Hsieh MS; Chiu CS; How CK; Chiang JH; Sheu ML; Chen WC; Lin HJ; Hsieh VC; Hu SY
Medicine (Baltimore); 2016 Apr; 95(16):e3388. PubMed ID: 27100424
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.
Pérez-Fontan M; Machado Lopes D; García Enríquez A; López-Calviño B; López-Muñiz A; García Falcón T; Rodríguez-Carmona A
PLoS One; 2016; 11(2):e0148806. PubMed ID: 26872254
[TBL] [Abstract][Full Text] [Related]
53. Beyond uncertainty: Negative findings for the association between the use of proton pump inhibitors and risk of dementia.
Park SK; Nam JH; Lee H; Chung H; Lee EK; Shin JY
J Gastroenterol Hepatol; 2019 Dec; 34(12):2135-2143. PubMed ID: 31145825
[TBL] [Abstract][Full Text] [Related]
54. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
55. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
56. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
57. Long-term mortality and risk factors for development of end-stage renal disease in critically ill patients with and without chronic kidney disease.
Rimes-Stigare C; Frumento P; Bottai M; Mårtensson J; Martling CR; Bell M
Crit Care; 2015 Nov; 19():383. PubMed ID: 26526622
[TBL] [Abstract][Full Text] [Related]
58. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs.
Eurich DT; Sadowski CA; Simpson SH; Marrie TJ; Majumdar SR
Am J Med; 2010 Jan; 123(1):47-53. PubMed ID: 20102991
[TBL] [Abstract][Full Text] [Related]
59. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
60. The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H
Gao J; Ma S; Xu S; Chen M
Dis Markers; 2022; 2022():4093595. PubMed ID: 35801003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
